Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Plavix is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome – For patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), Plavix has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) – For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of MI and stroke. FDA label
Clopidogrel Bisulfate · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Clopidogrel Bisulfate Tablets 75 mg |
| 2 | ACTIVE_COMPARATOR | Plavix® Tablets 75 mg |
| Name | Type | Description |
|---|---|---|
| Clopidogrel Bisulfate Tablets 75 mg | DRUG | 75mg, single dose fasting |
| Plavix® Tablets 75 mg | DRUG | 75mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have a negative serum (Beta HCG) pregnancy test performed within 14 days prior to the start of the study and on the evening prior to each dose administ...
Clopidogrel Bisulfate is a small molecule drug developed by Viatris Inc. (ticker VTRS). It is being studied in Phase 1 clinical development. The specific therapeutic indication for this program is undisclosed. It is also known as Clopidogrel Bisulfate Tablets 75 mg.
Clopidogrel Bisulfate targets P2RY12, a receptor that is classified as an antagonist target. By acting as an antagonist at P2RY12, the small molecule modulates the activity of this receptor. This mechanism defines how the drug is designed to work at the molecular level.
Clopidogrel Bisulfate is developed by Viatris Inc., which trades under the ticker symbol VTRS. Viatris is the sponsor responsible for the clinical development program of this small molecule drug candidate.
Clopidogrel Bisulfate is in Phase 1 clinical development. It is an investigational drug and is not approved. The program has completed two Phase 1 trials with a total enrollment of 93 participants. No active trials are currently listed for this drug.
Clopidogrel Bisulfate has been studied in two completed Phase 1 trials. NCT00650169 was a food study of Clopidogrel Bisulfate Tablets 75 mg versus Plavix Tablets 75 mg with 47 healthy volunteers. NCT00648947 was a fasting study of the same comparison with 46 healthy volunteers. Both were conducted in the United States.